-
Thrombosis Rates and Genetic Thrombophilia Risk Among Patients With Advanced Germ Cell Tumors Treated With Chemotherapy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-28 Landon C. Brown, Myra Robinson, Michael McCormack, Nury Steuerwald, James Symanowski, Wei Sha, Rupali Bose, Brittany Neelands, Tobi Akinyelu, Chad Livasy, Wencheng Li, Nathanael Haynes, Alicia Hamilton, Mathew Smith, Peter E. Clark, Jai Patel, Earle F. Burgess
Men with advanced germ cell tumors (GCT) treated with chemotherapy are at high risk of venous thromboembolism (VTE). Predictors of VTE may identify patients who would benefit from prophylactic anticoagulation. Men with advanced GCT (Stage IS, II, III) treated with chemotherapy were identified at 2 centers. High genomic risk was defined from a 5 single nucleotide polymorphism (SNP) germline panel. Logistic
-
Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-26 Anbang Wang, Ming Chen, Duocai Li, Jiazi Shi, Wenbin Tang, Zongqin Zhang, Shancheng Ren
To evaluate the efficacy and safety of a novel humanized anti-HER2 antibody, RC48-ADC (Disitamab vedotin, DV), the combination of RC48-ADC with PD-1 inhibitors was used to treat muscle-invasive bladder cancer (MIBC). This combination therapy has potential applications in both bladder preservation and neoadjuvant therapy for MIBC. Patients with MIBC underwent transurethral resection of bladder tumors
-
High Dose Chemotherapy With Autologous Stem Cell Transplant for Patients With Advanced Germ Cell Tumors: Real-World Evidence From a Tertiary Cancer Center in Brazil Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-24 Gabriel Berlingieri Polho, Mateus Trinconi Cunha, Maiana Hamdan Melo Coelho, Jamile Almeida-Silva, Cassio Murilo Hidalgo Filho, Erick Menezes Xavier, Nathalia de Souza Crusoe, Marcelo Junqueira Atanazio, Vitor Fiorin de Vasconcellos, Vivian Naomi Horita, Guilherme Fialho Freitas, David Queiroz Muniz, Vanderson Rocha, Jose Mauricio Mota
High-dose chemotherapy followed by stem cell transplant (HDCT) is potentially curative for patients with refractory germ cell tumors (rGCT). There is scarce real-world data supporting its implementation in low- and middle-income countries. We described the experience of our tertiary cancer center in Sao Paulo, Brazil. We identified male patients ≥18 years-old with rGCT referred to HDCT after board
-
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-23 Priyanka J. Bobbili, Jasmina Ivanova, David B. Solit, Niharika B. Mettu, Shannon J. McCall, Mallika Dhawan, Maral DerSarkissian, Bhakti Arondekar, Jane Chang, Alexander Niyazov, Jocelyn Lee, Risha Huq, Michelle Green, Michelle Turski, Phu Lam, Aruna Muthukumar, Tracy Guo, Manasi Mohan, Adina Zhang, Mei Sheng Duh, William K. Oh
There is currently limited literature assessing the real-world treatment patterns and clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations. Medical charts were abstracted for mCRPC patients with ≥ 1 of 12 HRR somatic gene alterations treated at US oncology centers participating in the American Association for
-
Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Renal Cell Carcinoma in England: A Retrospective Cohort Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-22 Prantik Das, Alison Booth, Robert Donaldson, Noami Berfeld, Beth Nordstrom, Robert Carroll, Poonam Dhokia, Andrew Clark, Luis Vaz
Considering the rapidly evolving treatment landscape of renal cell carcinoma (RCC), recent descriptions of the RCC population in the UK are lacking, as are real-world data on treatment and patient outcomes. To analyse the demographic and clinical characteristics, treatment patterns, and overall survival of patients with RCC using national data sets in England. This was a retrospective cohort study
-
Detection of the Highest-Grade Lesion in Multifocal Discordant Prostate Cancer by Multiparametric Magnetic Resonance Imaging Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-21 Kazuhiro Matsumoto, Hirotaka Akita, Akinori Hashiguchi, Toshikazu Takeda, Takeo Kosaka, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya, Masahiro Jinzaki
Prostate cancer generally occurs multifocally. The lesions of the largest size and highest-grade are often concordant, and defined as an index tumor. However, these factors sometimes do not coincide within one lesion. In such discordant cases, not the largest size lesion but the highest-grade lesion is known to determine the prognosis. We focused on the multiparametric magnetic resonance imaging (mpMRI)
-
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-21 Chisato Narita, Fumihiko Urabe, Wataru Fukuokaya, Kosuke Iwatani, Yu Imai, Keiji Yasue, Keiichiro Mori, Koichi Aikawa, Takafumi Yanagisawa, Shoji Kimura, Kojiro Tashiro, Shunsuke Tsuzuki, Yuta Yamada, Steffi Kar Kei Yuen, Jeremy Yuen-Chun Teoh, Tatsuya Shimomura, Hiroki Yamada, Akira Furuta, Jun Miki, Takahiro Kimura, JIKEI-YAYOI Collaborative Group
The CheckMate274 trial has reported enhanced disease-free survival rates in patients with stage pT3–4/ypT2–4 or pN+ urothelial carcinoma (UC) undergoing adjuvant nivolumab therapy. This study compares prognostic differences between urothelial carcinoma of the bladder (UCB) and upper tract urothelial carcinoma (UTUC). We retrospectively analyzed data from 719 patients with UC who underwent radical surgery
-
Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-21 Jakob Klemm, Shahrokh F. Shariat, Ekaterina Laukhtina, Pawel Rajwa, Malte W. Vetterlein, Victor M. Schuettfort, Markus von Deimling, Roland Dahlem, Margit Fisch, Michael Rink
We examined the impact of preoperative plasma potassium levels (PPLs) on outcomes in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB), hypothesizing that potassium imbalances might influence outcomes. In this retrospective study, 501 UCB patients undergoing RC from 2009 to 2017 at a tertiary center were analyzed. Blood samples collected a week prior to surgery
-
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-21 Kojiro Tashiro, Shoji Kimura, Shunsuke Tsuzuki, Fumihiko Urabe, Wataru Fukuokaya, Keiichiro Mori, Koichi Aikawa, Masaya Murakami, Hiroshi Sasaki, Kenta Miki, Jun Miki, Tatsuya Shimomura, Hiroki Yamada, Kenichi Hata, Hideomi Nishikawa, Hirokazu Abe, Ken Watanabe, Takahiro Kimura
-
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-19 Marco Stellato, Sebastiano Buti, Marco Maruzzo, Maria Bassanelli, Melissa Bersanelli, Marilena Di Napoli, Michele Dionese, Martina Fanelli, Roberto Filippi, Giuseppe Fotia, Luca Galli, Francesco Grillone, Michele Maffezzoli, Brigida Anna Maiorano, Cecilia Nasso, Sara Elena Rebuzzi, Luca Lalli, Giandomenico Roviello, Mariella Sorarù, Bruno Vincenzi, Giuseppe Procopio, Elena Verzoni
Peritoneal metastases (PM) have been reported in approximately 1% of patients with metastatic Renal Cell Carcinoma (mRCC). Outcome data are limited due to the rarity of this metastatic site. Therefore, the aim of our study is to describe renal cell carcinoma (RCC) patients with PM treated as per clinical practice. Baseline characteristics and outcome data of patients with PM from RCC were retrospectively
-
Clinical Outcomes and Prognostic Factors in Patients With Penile Carcinoma: A Sub-Analysis From Meet-URO 23 (I-RARE) Registry Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-18 Veronica Mollica, Francesco Massari, Marco Maruzzo, Davide Bimbatti, Melanie Claps, Brigida Anna Maiorano, Maria Giuseppa Vitale, Roberto Iacovelli, Paola Ermacora, Giandomenico Roviello, Fabio Calabrò, Orazio Caffo, Francesca Vignani, Francesco Grillone, Francesco Pierantoni, Marilena Di Napoli, Alessia Mennitto, Andrea Marchetti, Alvise Mattana, Alessia Cavo, Maria Bassanelli, Luigi Formisano, Veronica
Penile squamous cell carcinoma (PSCC) is a rare tumor with an aggressive behavior. The Meet-URO 23/I-RARE registry includes rare genitourinary malignancies. We extracted patients with PSCC to conduct a retrospective study aimed at assessing clinical outcomes and prognostic factors. Primary endpoints were overall survival and progression-free survival. Prognostic factors for OS and PFS were analyzed
-
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG) Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-15 Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, Sema Sezgin Goksu, Irem Bilgetekin, Burcu Cakar, Abdullah Sakin, Ozturk Ates, Tugba Basoğlu, Cagatay Arslan, Atike Gokcen Demiray, Semra Paydas, Irfan Cicin, Mehmet Ali Nahit Sendur, Nuri Karadurmus, Hakan Kosku, Aytuğ Uner, Perran Fulden Yumuk, Gungor Utkan, Umut Kefeli, Ozgur Tanriverdi, Havva Cınkır, Ozge Gumusay, Nazım Serdal Turhal, Serkan Menekse
Adrenocortical carcinoma (ACC) is a rare yet highly malignant tumor associated with significant morbidity and mortality. This study aims to delineate the clinical features, survival patterns, and treatment modalities of ACC, providing insights into the disease's prognosis. A retrospective analysis of 157 ACC patients was performed to assess treatment methodologies, demographic patterns, pathological
-
An Update on the Role of mpMRI and 68Ga-PSMA PET Imaging in Primary and Recurrent Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-13 Hamed Bagheri, Seyed Rabi Mahdavi, Parham Geramifar, Ali Neshasteh-Riz, Masoumeh Sajadi Rad, Habibollah Dadgar, Hossein Arabi, Habib Zaidi
-
A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-13 Syed Shariq Naeem, Pooja Gupta, Ranjit Kumar Sahoo, V.L. Kumar, T. Velpandian, Archana Singh, Atul Batra, Raja Pramanik, Sameer Rastogi, Saumya Srivastava
Hand foot skin reaction (HFSR) is a common dose-limiting adverse effect of multi kinase inhibitors (MKI) whose mechanism is not fully understood, and the prophylaxis is inadequate. In this pilot study, a double-blind, randomized placebo-controlled trial was conducted to evaluate the effect of topical urea in secondary prevention of sunitinib-induced HFSR in renal cell cancer patients. Out of 55 screened
-
NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Matthew Young, Jose C. Tapia, Bernadett Szabados, Agne Jovaisaite, Francesca Jackson-Spence, Elizabeth Nally, Thomas Powles
Reliable biomarkers in renal cell carcinoma (RCC) remain elusive. While several markers have been shown to be associated with prognosis, and may aid in risk assessment, predictive biomarkers of response to immune checkpoint inhibitors (ICIs) have not been established. Previous studies have shown that a high pretreatment neutrophil-lymphocyte ratio (NLR) is a negative prognostic factor in RCC. However
-
Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Cagri Akpinar, Digdem Kuru Oz, Alkan Oktar, Evren Suer, Eriz Ozden, Nuray Haliloglu, Omer Gulpinar, Mehmet Ilker Gokce, Cagatay Gogus, Sumer Baltaci
Recent guidelines suggest that biopsy may be omitted in some groups of patients with PI-RADS 3 lesions on mpMRI. In this study, we aimed to evaluate biopsy strategies involving prostate-specific antigen density (PSAd) to avoid unnecessary biopsy versus the risk of missing clinically significant prostate cancer (csPCa) in patients with PI-RADS 3 lesions. Data of 616 consecutive patients who underwent
-
Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Susu Zhou, Parissa Alerasool, Noriko Kishi, Himanshu Joshi, Gagan Sahni, Che-Kai Tsao
Second-generation androgen receptor axis-targeting (ARAT) agents have become a standard treatment for patients with advanced prostate cancer (PC), however much remains unknown about the potential cardiovascular toxicities. We performed a systematic search of PubMed, Embase, Web of Science, and Cochrane library for randomized controlled trials of patients receiving ARAT agents for PC from inception
-
Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-08 Jakob N. Henriksen, Charlotte U. Andersen, Niels Fristrup
Inter-individual variability in drug response pose significant challenges to treatment with tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma (mRCC). TKIs meet traditional criteria for using therapeutic drug monitoring (TDM), but research is still limited. Understanding the role of TDM in individualizing treatment strategies could help optimize treatment. Here we review
-
Development of a Nomogram Model to Identify Appropriate Candidates from Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Based on the Surveillance, Epidemiology and End Results Database Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-06 Kong Ren, Hao Ning, Hai-hu Wu, Fei Wu, Jia-ju Lyu
Although a survival benefit was observed in patients with metastatic renal cell carcinoma (mRCC) who underwent cytoreductive nephrectomy (CN), there is a lack of effective tools for predicting which individuals are likely to benefit from surgical intervention. Herein, we developed a predictive model using data from the Surveillance, Epidemiology, and End Results (SEER) database. Patients diagnosed
-
Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-05 Robert H. Mbilinyi, Pavlos Msaouel, Priya Rao, Jose A. Karam, Nizar M. Tannir, Chad Tang
Renal medullary carcinoma (RMC) is a rare and aggressive cancer that occurs in young individuals of African descent with sickle cell trait. Unlike renal cell carcinoma with a five-year overall survival rate of up to 77%, fewer than 5% of patients with RMC survive beyond 3 years with standard systemic therapies. RMC responds poorly to treatments effective for other renal malignancies. This highlights
-
Effectiveness of Adjuvant Chemotherapy in Variant Histology Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Stabilized Inverse Probability Treatment Weighting Analysis of Single Center Experience Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-04 Inkeun Park, Jungyo Suh, Bumjin Lim, Cheryn Song, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Yong Mee Cho, Jaelyun Lee, Bumsik Hong
The study aimed to investigate the impact of adjuvant chemotherapy on time to recurrence (TTR) and overall survival (OS) in patients with histologic variants of upper tract urothelial carcinoma (VUTUC) following radical nephroureterectomy (RNU). A retrospective review of 131 VUTUC patients' medical records, from a pool of 368 non-metastatic localized or locally advanced UTUC cases, treated at a single
-
IMPROVER (Involving Men with Prostate Cancer in Engaged Research): Assessing Patient Experience With Testing, Diagnosis, And Surveillance Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-04 Marc Walsh, Asia Jordan, Lea Schäfer, Jana Joha, Ben Heapes, Megan Noonan, William Gallagher, Hubert Gallagher, Rustom P. Manecksha, David Galvin, Greg Nason, Terri Martin, Ciara Lyons, Robert O'Connor, UCD Prostate Patient Advisory Committee, Frances J. Drummond, Claire Kilty, Antoinette S. Perry
Our understanding of patient experiences with prostate cancer testing for diagnosis and surveillance is limited. The aim of this study was to collaborate with patients and clinicians to understand their lived experience and unmet needs around the early detection, diagnosis and monitoring (active surveillance) of prostate cancer. Two focus groups were held with patients (n = 20) and healthcare professionals
-
Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-03-02 Zuzana Orszaghova, Dominika Galikova, Peter Lesko, Jana Obertova, Katarina Rejlekova, Zuzana Sycova-Mila, Patrik Palacka, Katarina Kalavska, Daniela Svetlovska, Beata Mladosievicova, Jozef Mardiak, Michal Mego, Michal Chovanec
Chemotherapy-induced peripheral neuropathy (CIPN) after curative treatment for testicular germ cell tumors (GCTs) has been previously reported. It has been shown that CIPN can contribute to impaired quality of life (QOL) in cancer survivors. Herein, we aimed to evaluate CIPN in association with QOL in GCT survivors. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life
-
A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non–Muscle-Invasive Bladder Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-29 Dengxiong Li, Ruicheng Wu, Jie Wang, Junjiang Ye, Qingxin Yu, Dechao Feng, Ping Han
In order to develop a model for predicting the response to Bacillus Calmette-Guerin (BCG) treatment in patients with nonmuscle invasive bladder cancer, we included inflammatory and nutritional indicators from a cohort of 491 patients. We constructed a prognostic index using a Lasso regression model and validated its effectiveness, demonstrating its potential for clinical application.
-
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-28 Jazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, Ahmed El-Zawahry, James Peabody, Tiffany Pearce, Nicole Adams, Mustafa Deebajah, Danuta Dynda, Kara Babaian, Jane Crabtree, Kristin Delfino, Kevin McVary, Kathy Robinson, Krishna Rao, Shaheen Alanee
To report urinary bother, urinalysis changes, disease-free survival (DFS), and overall survival (OS) over 2 years for subjects enrolled in a phase I dose-escalation trial (NCT02324582) of intravesical Bacillus Calmette-Guérin (BCG) in combination with systemic pembrolizumab for recurrent or persistent high-grade non-muscle invasive bladder cancer (HGNMIBC). Eighteen patients consented to the study
-
Telemedicine for Multidisciplinary Urologic Cancer Care: A Prospective Single Institution Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-24 Frederick Okoye, Adam J. Gadzinski, Rishi Sekar, Isabelle Abarro, Petros Grivas, Scott S. Tykodi, Jay Liao, Jonathan Chen, Jing Zeng, Jonathan Wright, John L. Gore
We rapidly implemented a telemedicine Multidisciplinary Urologic Cancer Clinic (MDUCC) at the University of Washington/Seattle Cancer Care Alliance during the peak of the COVID-19 Public Health Emergency to maintain our ability to provide multidisciplinary cancer care. We report our experiences though assessment of patient-reported outcomes from our telemedicine MDUCC. Video visits with a urologic
-
Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis) Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-23 Jeffrey Graham, Sunita Ghosh, Rodney H. Breau, Lori Wood, Simon Tanguay, Dominick Bosse, Aly-Khan Lalani, Bimal Bhindi, Daniel Heng, Antonio Finelli, Nazanin Fallah-Rad, Vincent Castonguay, Naveen S. Basappa, Denis Soulières, Frédéric Pouliot, Christian Kollmannsberger, Georg A. Bjarnason
This retrospective study assessed the impact of cabozantinib dose reductions on outcomes in metastatic renal cell carcinoma (mRCC). Patients requiring dose reductions experienced significantly better overall survival and time to treatment failure. These findings underscore the potential of using on-treatment toxicity as an indicator of adequate drug exposure to individualize dosing and optimize treatment
-
Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-17 Kassandra Dindinger-Hill, Siqi Hu, Atticus Hickman, Mouneeb Choudry, Jeffrey Vehawn, John Snyder, Vikrant Deshmukh, Michael Newman, Ankita Date, Carlos Galvao, Manish Kohli, Brock O'Neil, Bogdana Schmidt, Christopher Dechet, Mia Hashibe, Alejandro Sanchez
Obesity in prostate cancer survivors may increase mortality. We performed a retrospective cohort analysis of 5,077 patients diagnosed with localized prostate cancer from 1997 to 2017. We found post-diagnosis obesity increased the risk of cardiovascular disease specific and all-cause mortality relative to non-obese men. An increased emphasis on weight management may improve mortality for prostate cancer
-
Linear Muscle Segmentation for Metastatic Renal Cell Carcinoma: Changes in Clinic-Friendly Estimation Predict Survival Following Cytoreductive Nephrectomy Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-16 Edouard H. Nicaise, Benjamin N. Schmeusser, Adil Ali, Eric Midenberg, Arnold R. Palacios, Blaise Hartsoe, Ethan Kearns, Sriram Ambadi, Dattatraya H. Patil, Shreyas S. Joshi, Vikram M. Narayan, Sarah P. Psutka, Bassel Nazha, Jacqueline T. Brown, Kenneth Ogan, Mehmet A. Bilen, Viraj A. Master
Baseline sarcopenia and postoperative changes in muscle mass are independently associated with overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) undergoing cytoreductive nephrectomy (CN). Here we examine the relationships between preoperative (baseline), postoperative changes in muscle quantity, and survival outcomes following CN as determined by linear segmentation, a clinic-friendly
-
Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-15 Sarah Fleming, Dina Gifkins, Helaine E. Resnick, Waleed Shalaby, Philip Rosenberg, Chris Gaj, Vittorio Maio, Albert Crawford, Grace Lu-Yao, Jianjun Gao, Arlene Siefker-Radtke
To understand the impact of genetic alterations on disease progression in metastatic urothelial carcinoma, physician-provided clinical data from 414 patients was assessed. In patients treated with first-line immune checkpoint inhibitors only, those with alterations had significantly higher rates of progression than patients with wild-type . Understanding the impact of alterations on disease progression
-
The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-15 Margaret Meagher, Kylie M. Morgan, Leah Deshler, Dhruv Puri, Kit Yuen, Aditya Bagrodia, Brent Rose, Tyler Stewart, Amirali Salmasi
The role of local definitive therapy in addition to systemic treatment in clinically positive regional lymph node (cN+) bladder cancer is yet to be determined. Herein, we sought to investigate the role of radical cystectomy (RC) in management of patients with cN+ bladder cancer at US Veterans Health Administration Facilities. We identified patients diagnosed with cN+ bladder cancer between 2000-2017
-
Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-14 Nguyen Xuong Duong, Minh-Khang Le, Tuan Thanh Nguyen, Duy Duc Nguyen, Huy Gia Vuong, Tetsuo Kondo, Takahiko Mitsui
Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web
-
Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-12 Xin Wang, Larissa Waldman, Yael Silberman, Michael Wang, Caleb Tackey, Lilian Hanna, Danny Vesprini, Urban Emmenegger, Andrea Eisen, Martin Smoragiewicz
An estimated 20% to 30% of men with advanced prostate cancer carry a mutation in DNA damage repair genes, of which half are estimated to be germline. Eligibility criteria for germline genetic testing expanded significantly for Ontario patients in May 2021 and many centers adopted a “mainstream” model, defined as oncologist-initiated genetic testing. We conducted a retrospective chart review to report
-
Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-09 Shugo Yajima, Yasukazu Nakanishi, Ryo Andy Ogasawara, Naoki Imasato, Kohei Hirose, Sao Katsumura, Madoka Kataoka, Hitoshi Masuda
Sarcopenia is a condition of low muscle strength and quantity, severe if low physical performances. The sarcopenia index (SI), calculated by blood levels of creatinine and cystatin C, had been reported to be correlated with skeletal muscle mass and is a potential simple screening tool for sarcopenia. We hypothesized that patients with a low SI, meaning low muscle mass, would have an inflated estimated
-
Clinical Profile and Outcomes of Carcinoma Penis Patients Receiving Systemic Therapy at an Indian tertiary care Center: A Retrospective Observational Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-07 Vanita Noronha, Venkatesh Kapu, Amit Joshi, Nandini Menon, Ajaykumar Singh, Gagan Prakash, Santosh Menon, Nilesh Sable, Vedang Murthy, Mahendra Pal, Amandeep Arora, Sravan Kumar, Shripad Banavali, Kumar Prabhash
Penile carcinoma is rare and data are scarce. Observational study at Tata Hospital (Mumbai) on 91 patients. In 19 patients treated with neoadjuvant paclitaxel + platinum, ORR=37%, surgical resection rate=31.5%. Med OS in 71 patients treated with curative intent was 33.8 months. In 20 patients treated with palliative chemotherapy, ORR-20%, mediatn OS=11.4 months
-
The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-06 Luna van den Brink, Annebeth E. C. Ruiter, Brunolf W. Lagerveld, Niels M. Graafland, Axel Bex, Harrie P. Beerlage, Jeroen R. A. van Moorselaar, Patricia J. Zondervan
To describe the impact of a multidisciplinary tumor board (MTB) for renal cell carcinoma (RCC) patients in a locoregional renal cancer network by evaluating shared decision making (SDM) and adherence to MTB recommendations. This prospective cohort study included all cases from a Dutch renal cancer network with suspicion of or histologically confirmed RCC discussed in MTBs between 2017-2022. Main endpoints
-
Ejaculation Frequency and Prostate Cancer Risk: A Narrative Review of Current Evidence Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Emmanuel Kokori, Gbolahan Olatunji, David Timilehin Isarinade, John Ehi Aboje, Ikponmwosa Jude Ogieuhi, Zainab Doyinsola Lawal, Nathnael Abera Woldehana, Muhammad Wajeeh Nazar, Godfred Yawson Scott, Nicholas Aderinto
Prostate cancer, constituting a substantial portion of global cancer incidence and mortality, prompts a critical examination of potential modifiers, notably ejaculation frequency. This narrative review explores the complex relationship between ejaculation frequency and prostate cancer risk, addressing the paucity of consensus and the intricate interplay of factors. The evidence drawn from eleven studies
-
Recurrent bacteriuria as a prognosis marker in the adjuvant treatment of non-muscle invasive bladder cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Juliusz J. Szczesniewski, Magaly T. Márquez-Sánchez, Bárbara Padilla-Fernández, Luis Llanes-González, María F. Lorenzo-Gómez
Purpose : Bacteriuria may affect the response to adjuvant therapy in non-muscle invasive bladder cancer (NMIBC). The main aim of this study was to examine the effect of recurrent bacteriuria (RB) on the prognosis of NMIBC in women receiving intravesical therapy. Materials and methods : We designed a prospective observational study from 2012 to 2019. We included women with bladder cancer treated with
-
Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021. Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-02 Jose C. Tapia, Freya Bosma, Javier Gavira, Sofia Sanchez, Maria Alejandra Molina, Judit Sanz-Beltran, Cristina Martin-Lorente, Georgia Anguera, Pablo Maroto
Metastatic urothelial carcinoma (mUC) is a lethal disease with limited treatment options. We aimed to compare the treatment patterns and outcomes of patients with mUC who were treated before and after the introduction of immune checkpoint inhibitors (ICIs) at a tertiary hospital in Barcelona. Single-centre retrospective study from 2004 to 2021. Access to ICIs began in December 2014. We analysed differences
-
Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Carolin Siech, Simone Morra, Lukas Scheipner, Andrea Baudo, Letizia M.I. Jannello, Mario de Angelis, Jordan A. Goyal, Zhe Tian, Fred Saad, Shahrokh F. Shariat, Nicola Longo, Luca Carmignani, Ottavio de Cobelli, Sascha Ahyai, Alberto Briganti, Philipp Mandel, Luis A. Kluth, Felix K.H. Chun, Pierre I. Karakiewicz
The association between treatment rates and cancer specific mortality (CSM) according to married status in male and female clear cell renal cell carcinoma (ccRCC) patients across all stages is unknown. Using the Surveillance, Epidemiology, and End Results database (2004-2020), ccRCC patients were stratified according to married status (married vs. unmarried). Logistic regression models addressed treatment
-
Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Tenaw Tiruye, Michael O'Callaghan, Liesel M. FitzGerald, Kim Moretti, Alex Jay, Braden Higgs, Ganessan Kichenadasse, Gillian Caughey, David Roder, Kerri Beckmann
We aimed to assess the association between comorbidities and prostate cancer management. We studied 12,603 South Australian men diagnosed with prostate cancer between 2003 and 2019. Comorbidity was measured one year prior to prostate cancer diagnosis using a medication-based comorbidity index (Rx-Risk). Binomial logistic regression analyses were used to assess the association between comorbidities
-
Urological Cancers and ChatGPT: Comment Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-02-01 Amnuay kleebayoon, Viroj Wiwanitkit
Abstract not available
-
-
Carboplatin in Metastatic Castrate Resistant Prostate Cancer: A Retrospective Study of Heavily Pretreated Patients (COMPACT) Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-22 Lara Pemberton, Connor Allen, Eleanor Handel, Andrew Weickhardt, Jeremy Shapiro, Ben Tran, Renea A. Taylor, Gail P. Risbridger, David W. Pook
Many clinicians consider carboplatin monotherapy in advanced castrate-resistant prostate cancer (CRPC) patients who have progressed through all available hormonal and standard chemotherapy treatment options, despite the limited evidence to justify its use. This retrospective analysis aimed to evaluate the use of carboplatin monotherapy in patients with refractory prostate cancer in Australia. Efficacy
-
Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-22 Hejia Yuan, Tianqi Wang, Peng Peng, Zhunan Xu, Fan Feng, Yuanshan Cui, Jian Ma, Jitao Wu
Urothelial bladder cancer (BCa) is a common malignant tumor of the urinary system. It has been identified that exosomal miRNAs contribute to the development of BCa. However, its significance and mechanism in the malignant biological behavior of BCa remain unclear. In this study, the influence of exosomal miRNAs on BCa progression was investigated. High-throughput sequencing was conducted to analyze
-
Incidental Coronary Arterial Calcification for Cardiovascular Risk Assessment in Men With Prostate Cancer Undergoing PET/CT Imaging Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-22 Preet A. Shaikh, Avira Som, Elena Deych, Alison J. Deng, Melissa A. Reimers, Brian C. Baumann, Eric H. Kim, Daniel J. Lenihan, Kathleen W. Zhang
Cardiovascular (CV) disease is common among men with prostate cancer and the leading cause of death in this population. There is a need for CV risk assessment tools that can be easily implemented in the prostate cancer treatment setting. Consecutive patients who underwent positron emission tomography/computed tomography (PET/CT) for recurrent prostate cancer at a single institution from 2012 to 2017
-
A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-20 Daniel Boiarsky, Doga C. Gulhan, Hunter Savignano, Gitanjali Lakshminarayanan, Heather M. McClure, Rebecca Silver, Michelle S. Hirsch, Lynette M. Sholl, Atish D. Choudhury, Guruprasad Ananda, Peter J. Park, Alok K. Tewari, Jacob E. Berchuck
Immune checkpoint inhibitors (ICIs) have limited efficacy in prostate cancer (PCa). Better biomarkers are needed to predict responses to ICIs. We sought to demonstrate that a panel-based mutational signature identifies mismatch repair (MMR) deficient (MMRd) PCa and is a biomarker of response to pembrolizumab. Clinico-genomic data was obtained for 2664 patients with PCa sequenced at Dana-Farber Cancer
-
The Prognostic Value of Tumor Infiltrating Lymphocytes After Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-17 Tatsushi Kawada, Takafumi Yanagisawa, Pawel Rajwa, Reza Sari Motlagh, Hadi Mostafaei, Fahad Quhal, Ekaterina Laukhtina, Maximilian Pallauf, Frederik König, Benjamin Pradere, Motoo Araki, Yasutomo Nasu, Shahrokh F. Shariat
We aimed to assess the prognostic value of tumor infiltrating lymphocytes (TILs) in patients with bladder cancer (BC) after radical cystectomy (RC). We searched Pubmed, Web of Science and Scopus in April 2022 to identify studies assessing the prognostic value of TILs, including a subset of lymphocytes (eg, CD3, CD8, FOXP3), after RC. The endpoints were overall survival and recurrent free survival.
-
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-15 Hiroki Ishihara, Yuki Nemoto, Hidekazu Tachibana, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi
It remains unclear whether kidney function affects outcomes following immune checkpoint inhibitor (ICI)-based combination therapy for advanced renal cell carcinoma (RCC). We retrospectively evaluated data of 167 patients with advanced RCC, including 98 who received ICI dual combination therapy (ie, immunotherapy [IO]-IO) and 69 who received ICI combined with tyrosine kinase inhibitor (TKI) (ie, IO-TKI)
-
Surveillance or Dynamic Sentinel Lymph-Node Biopsy in Low-Risk Clinically N0 Penile Squamous Cell Carcinoma: Single-Institution Real World Data Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-15 Sebastiano Nazzani, Mario Catanzaro, Martina Bruniera, Tullio Torelli, Alberto Macchi, Silvia Stagni, Antonio Tesone, Carlo Silvani, Tommaso Ceccato, Valentina Bernasconi, Rodolfo Lanocita, Tommaso Cascella, Melanie Claps, Patrizia Giannatempo, Matteo Zimatore, Laura Cattaneo, Davide Biasoni, Emanuele Montanari, Nicola Nicolai
Surveillance is the standard management in low-risk cN0 penile squamous cell carcinoma (peSCC) patients. However, no previous analysis focused on early and long-term outcomes of these patients. We report on main oncological outcomes of a large series of low-risk cN0 peSCC patients. Between 1980 and 2017 included, 93 evaluable consecutive low-risk (ie, pT1a G1 cN0M0) peSCC patients underwent primary
-
Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-14 Martina Catalano, Ugo De Giorgi, Davide Bimbatti, Sebastiano Buti, Giuseppe Procopio, Pierangela Sepe, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello
Although in metastatic renal cell carcinoma (mRCC) patients with intermediate and poor risk the benefit of combination strategies versus tyrosine kinase inhibitor (TKI) has been ascertained, in those with favorable risk data are ambiguous. Herein, we investigated the impact of number and type of metastatic site in patients with favorable risk to contribute to the best therapeutic choice. Multicenter
-
SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-12 Aimin Jiang, Ying Liu, Baohua Zhu, Yu Fang, Le Qu, Qiwei Yang, Peng Luo, Chen Cai, Linhui Wang
The emerging evidence suggested that senescence regulator genes were involved in multi cancers, which may be utilized as new targets for cancers. However, the dysregulation and clinical impact of senescence regulator genes in clear cell renal cell cancer (ccRCC) were still in foggy. Using multiomics data from TCGA-KIRC and other datasets, we comprehensively investigated the function of senescence regulator
-
Cystic Pelvic Masses in Men: A Presentation of Uncommon Cases and a Literature Review Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-11 Constantin Rieger, David Pfister, Lucas Kastner, Marie-Lisa Eich, Alexander Quaas, Yuri Tolkach, Axel Heidenreich
Unclear cystic masses in the pelvis in male patients are a rare situation and could be of benign or malignant origin. The underlying diseases demand for specific diagnostic and therapeutic approaches. We present a case series of 3 male patients with different clinical symptoms (perineal pain, urinary retention and a large scrotal cyst) related to cystic lesions in the pelvic region. On all patients
-
The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-10 Obaid Ur Rehman, Zain Ali Nadeem, Eeshal Fatima, Umar Akram, Hiba Imran, Ali Husnain, Arsalan Nadeem, Waqas Rasheed
Castration resistant prostate cancer (CRPC) is a challenging subset of prostate cancer associated with an extensive metastatic profile and high mortality. Ketoconazole is a nonselective steroid 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor and is employed as a second line treatment option for CRPC with an established efficacy profile in patients. The aim of this study is to assess the efficacy of
-
Bladder-Preserving Trimodality Therapy With Capecitabine Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-09 Connor Lynch, Randy F. Sweis, Parth Modi, Piyush K. Agarwal, Russell Z. Szmulewitz, Walter M. Stadler, Peter H. O'Donnell, Stanley L. Liauw, Sean P. Pitroda
Many patients with muscle-invasive bladder cancer are poor candidates for radical cystectomy or trimodality therapy with maximal transurethral resection of bladder tumor (TURBT) and chemoradiotherapy with cisplatin or mitomycin C. Given the benefit of chemotherapy in bladder-preserving therapy, less-intense concurrent chemotherapy regimens are needed. This study reports on efficacy and toxicity for
-
The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-09 Daeun Sung, Bogdana Schmidt, Jonathan David Tward
The International Staging Collaboration for Prostate Cancer (STAR-CAP) has been proposed as a risk model for prostate cancer with superior prognostic power compared to the current staging system. This study aimed to evaluate the performance of STAR-CAP in predicting the risk of subsequent therapy after initial treatment and the risk of developing metastases. The study included 3425 men from an institutional
-
Bladder Cancer and the Urinary Microbiome—New Insights and Future Directions: A Review Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-09 Angela E. Russo, Areeba Memon, Shahid Ahmed
The presence of a microbiome in the urinary system has been established through recent advancements in technology and investigation of microbial communities in the human body. The study of the taxonomic and genomic ecology of microbial communities has been greatly improved by the use of metagenomics. The research in this area has expanded our understanding of microbial ecosystems and shows that the
-
Assessing the Impact of Percutaneous Nephrostomy Presence on Neoadjuvant Treatment Quality in Patients With Muscle Invasive Bladder Cancer Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-06 Ziv Savin, Roy Mano, Alon Lazarovich, Barak Rosenzweig, Reut Shashar, Azik Hoffman, Ilona Pilosov, Yuval Freifeld, Sagi Arieh Shpitzer, Shay Golan, Ofer Yossepowitch, Mario Sofer
Symptomatic hydronephrosis associated with muscle invasive bladder cancer (MIBC) necessitates percutaneous nephrostomy (PCN) insertion before neoadjuvant chemotherapy (NAC). This study assesses the impact of PCN presence on standard intended NAC quality, its related complications and outcome after radical cystectomy (RC). The study comprises a retrospective, multicenter cohort of 193 consecutive RCs
-
Urological Cancers and ChatGPT: Assessing the Quality of Information and Possible Risks for Patients Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-05 Faruk Ozgor, Ufuk Caglar, Ahmet Halis, Hakan Cakir, Ufuk Can Aksu, Ali Ayranci, Omer Sarilar
OpenAI has created ChatGPT, an artificial intelligence language model that has gained considerable recognition for its capacity to produce text responses resembling human language. Consequently, this study seeks to evaluate the effectiveness of ChatGPT's responses in addressing publicly accessible queries related to prostate, kidney, bladder, and testicular cancers. A comprehensive compilation of frequently
-
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study Clin. Genitourin. Cancer (IF 3.2) Pub Date : 2024-01-04 Mona Kafka, Giulia Giannini, Nastasiia Artamonova, Hannes Neuwirt, Heidemarie Ofner, Gero Kramer, Thomas Bauernhofer, Ferdinand Luger, Thomas Höfner, Wolfgang Loidl, Hubert Griessner, Lukas Lusuardi, Antonia Bergmaier, Andreas Berger, Thomas Winder, Sarah Weiss, Severin Bauinger, Steffen Krause, Martin Drerup, Elmar Heinrich, Magdalena Schneider, Stephan Madersbacher, Sonia Vallet, Franz Stoiber, Sarah
Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus changing treatment strategies in metastatic hormonesensitive prostate cancer (mHSPC). We conducted the first real-world analysis comprising 97 mHSPC patients from 16 Austrian medical